LucentAD® Complete
Assessment of Alzheimer's Disease Pathology
CommercialActively marketed and available
Key Facts
Indication
Assessment of Alzheimer's Disease Pathology
Phase
Commercial
Status
Actively marketed and available
Company
About Lucent Diagnostics
Lucent Diagnostics is dedicated to transforming Alzheimer's detection and diagnosis by making highly-sensitive, accessible blood tests the new standard of care. Its core offerings are the LucentAD® Complete and LucentAD® p-Tau217 tests, which utilize the ultrasensitive Simoa® platform to identify Alzheimer's-related biomarkers. As a commercial-stage diagnostics brand under the publicly-traded Quanterix Corporation, it aims to empower healthcare providers with tools for earlier intervention and improved patient outcomes in the rapidly evolving Alzheimer's therapeutic landscape.
View full company profile